ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1791

Point-of-Care Multi-Energy Photon-Counting CT for Earlier Non-Invasive Diagnosis of Gout and Calcium Pyrophosphate Deposition Disease

Fabio Becce1, Anais Viry2, Damien Racine2, David Rotzinger1, Tristan Pascart3, Georgios Filippou4, Jérôme Damet2 and Lucia Gallego Manzano2, 1Lausanne University Hospital (CHUV), Lausanne, Switzerland, 2Institute of Radiation Physics, Lausanne, Switzerland, 3Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, 4Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy

Meeting: ACR Convergence 2022

Keywords: Computed tomography (CT), CPPD, Crystal-induced arthritis, gout, Imaging

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: While the definitive diagnosis of gout and calcium pyrophosphate deposition disease (CPPD) is still based on the identification of characteristic crystals in synovial fluid or tophus, imaging ‒ in particular ultrasound and dual-energy computed tomography (DECT) ‒ is playing an increasingly important role [1]. However, the performance of DECT remains limited by potential artifacts and its minimum spatial resolution (down to ≈250 µm), which lowers its sensitivity and prevents early diagnosis in patients with small crystal deposition volumes. Thanks to its higher spatial resolution (down to ≈100 µm), emerging multi-energy/spectral photon-counting CT (PCCT) has the potential to identify monosodium urate (MSU) and calcium pyrophosphate (CPP) crystal deposition earlier. In this phantom study, we aimed to assess whether point-of-care PCCT can identify smaller deposits of MSU and CPP crystals than DECT.

Methods: We used a soft tissue phantom with synthetic crystal inserts with known concentrations of MSU (200-600 mg/mL) and CPP (50-200 mg/mL). Crystals were suspended in a crystal-free background mimicking synovial tissue attenuation. Concentrations were selected to cover the range of X-ray attenuation characteristics encountered in vivo for MSU and CPP crystal deposits [3, 4]. The phantom was successively scanned using a last-generation DECT operated at 70 and 140 kVp, and a novel point-of-care PCCT system operated at 118 kVp. A single dose level of 3 mGy was used for both CT systems. PCCT images were reconstructed in five non-overlapping energy bins (7-40, 40-50, 50-60, 60-79, and 79-118 keV) at an isotropic voxel size of 0.1×0.1×0.1 mm3. Areas under the curve (AUC) were computed for each crystal suspension pair and with the crystal-free background. We also calculated the minimum pixel sample size (with its corresponding diameter) required to distinguish between two crystal types within a deposit, using the same method as in [2].

Results: Overall, the diagnostic performance of PCCT in identifying MSU and CPP crystal deposits was greater than or equal to that of DECT. When distinguishing between MSU and CPP, diagnostic accuracy was excellent for both PCCT (AUC=0.980, [95%CI=0.960-0.993]) and DECT (AUC=1, [95%CI=1-1]). In contrast, diagnostic accuracy of PCCT (AUC=0.984, [95%CI=0.933-0.994] for MSU; and AUC=0.998, [95%CI=0.994-1.0] for CPP) outperformed that of DECT (AUC=0.650, [95%CI=0.450-0.830] for MSU; and AUC=0.729, [95%CI=0.556-0.903] for CPP) for the identification of both MSU and CPP in a crystal-free background. The minimum pixel sample size required to distinguish between MSU and CPP within a crystal deposit decreased from 3 pixels (0.4 mm diameter) with DECT to 2 pixels (0.2 mm diameter) with PCCT. On the other hand, DECT needed a minimum of 3-4 pixels (0.5 mm diameter) to differentiate between MSU and CPP within a crystal-free soft tissue background, whereas PCCT required minimum sample sizes of 2-3 pixels (0.2 mm diameter) to perform this same diagnostic task.

Conclusion: Point-of-care PCCT can identify smaller volumes of MSU and CPP crystal deposits with comparable accuracy to DECT. Optimization of PCCT protocols should further improve crystal characterization at very high spatial resolution.


Disclosures: F. Becce, Horizon Therapeutics, Siemens Healthineers; A. Viry, None; D. Racine, None; D. Rotzinger, None; T. Pascart, None; G. Filippou, None; J. Damet, None; L. Gallego Manzano, None.

To cite this abstract in AMA style:

Becce F, Viry A, Racine D, Rotzinger D, Pascart T, Filippou G, Damet J, Gallego Manzano L. Point-of-Care Multi-Energy Photon-Counting CT for Earlier Non-Invasive Diagnosis of Gout and Calcium Pyrophosphate Deposition Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/point-of-care-multi-energy-photon-counting-ct-for-earlier-non-invasive-diagnosis-of-gout-and-calcium-pyrophosphate-deposition-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/point-of-care-multi-energy-photon-counting-ct-for-earlier-non-invasive-diagnosis-of-gout-and-calcium-pyrophosphate-deposition-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology